Aging brain

The McKnight Brain Research Foundation Releases Survey Showing Majority of People Feel Uninformed About What's Normal and What to Expect as the Brain Ages

Retrieved on: 
Friday, March 22, 2024
Research, Depression, Friends, Brain, Organization, Mental health, Dementia, Exercise, Learning, Brain Works, Memory, Vegetable, Diabetes, Risk, Heart rate, Conditional sentence, Aging brain, Sleep, Perspiration, Anxiety, Doctor of Philosophy, MD, Thought, Albert Einstein's brain, Body, Amnesia, Diet, Fruit, Language, Family, Ageing, Fear, Mobile phone

ORLANDO, Fla., March 22, 2024 /PRNewswire/ -- The McKnight Brain Research Foundation (MBRF) today released findings from a new survey showing one-third of Americans feel uninformed about normal brain aging. In addition, 87% of Americans are concerned about experiencing age-related memory loss and a decline in brain function as they grow older. To educate the public about normal brain aging, also known as cognitive aging, the MBRF is launching a new campaign, Brain Works – Optimize Your Brain Span. 

Key Points: 
  • Foundation Launching New Campaign – Brain Works: Optimize Your Brain Span –
    ORLANDO, Fla., March 22, 2024 /PRNewswire/ -- The McKnight Brain Research Foundation (MBRF) today released findings from a new survey showing one-third of Americans feel uninformed about normal brain aging.
  • To educate the public about normal brain aging, also known as cognitive aging, the MBRF is launching a new campaign, Brain Works – Optimize Your Brain Span.
  • "For the past 25 years, the McKnight Brain Research Foundation has been a leading supporter of research to better understand and alleviate the effects of age-related cognitive decline and memory loss," said Michael L. Dockery, MD, Chair of the McKnight Brain Research Foundation.
  • The MBRF survey showed that only 32% of respondents believe they can take action to help control their brain health as they age.

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.

Retrieved on: 
Wednesday, July 12, 2023
Heart, Obesity, Drug development, Diet, Rejuvenation, Apolipoprotein E, Prevalence, Life, Diabetes, Inflammaging, Albert Einstein's brain, Overalls, DSM-IV codes, Quality of life, Cross, Brain, Research, Inflammation, Biomarker, Autoimmunity, Trial of the century, Cellular senescence, Literature, Pesticide, Aging brain, MD, Patient, Tesi, Conditional sentence, Health, AD, Smoking, Conference, Foundation for the National Institutes of Health, Neuroinflammation, Disease, Medical imaging, Ageing

Boca Raton, Florida, July 12, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease has been invited to discuss drug development strategies in aging and rejuvenation at the 5th World Aging and Rejuvenation Conference in Frankfurt, Germany on July 17, 2023.

Key Points: 
  • Chronic diseases of aging affect virtually every organ system, including the heart, brain, eyes, ears, bones, and skeletal muscles.
  • Unfortunately, they contribute to a diminished health span, resulting in shortened life spans, increased elder care costs, and reduced quality of life.
  • “Cognitive aging is a well-defined disease that has not been the subject of extensive clinical study or intervention,” said CJ Barnum, VP CNS Development at INmune Bio.
  • Unfortunately, no treatments currently exist for inflammaging.”
    “The field of aging research and drug development has many challenges,” said RJ Tesi, MD, CEO of INmune Bio said.

Researchers Use AI to Track Cognitive Deviation in Aging Brains

Retrieved on: 
Wednesday, June 23, 2021
Psychiatric diagnosis, Branches of biology, Cognitive disorders, Learning disabilities, Psychiatry, Neuroscience, Mild cognitive impairment, Alzheimer's disease, Dementia, Aging brain, Alzheimer's Disease Neuroimaging Initiative, Cognitive intervention

The model has the potential to aid in early detection of cognitive impairment at an individual level.

Key Points: 
  • The model has the potential to aid in early detection of cognitive impairment at an individual level.
  • Amnestic mild cognitive impairment (aMCI) is a transition phase from normal aging to Alzheimer's disease (AD).
  • The researchers also examined the associations between the predicted age difference and cognitive impairment, genetic risk factors, pathological biomarkers of AD, and clinical progression in aMCI patients.
  • "Accelerated Brain Aging in Amnestic Mild Cognitive Impairment: Relationships with Individual Cognitive Decline, Risk Factors for Alzheimer Disease and Clinical Progression."

DiamiR Receives USPTO Notice of Allowance For Key Patent Covering the Use of Circulating Brain-Enriched microRNA Biomarkers for Monitoring of Brain Aging; Provides Update on Its Patent Portfolio

Retrieved on: 
Wednesday, May 27, 2020
Branches of biology, Biology, Medicine, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Biomarkers, microRNA, Alzheimer's disease, Mild cognitive impairment, Aging brain

"The patent covers the use of methods developed by DiamiR based on targeted quantitative analysis of microRNAs enriched in the brain and detectable in blood plasma as biomarkers of brain aging.

Key Points: 
  • "The patent covers the use of methods developed by DiamiR based on targeted quantitative analysis of microRNAs enriched in the brain and detectable in blood plasma as biomarkers of brain aging.
  • DiamiR is currently developing its first diagnostic product, CogniMIR, for early detection and prediction of progression of early Alzheimer's disease and mild cognitive impairment.
  • Such microRNAs can be effective, patient-friendly biomarkers reflective of processes underlying brain health and aging.
  • These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially.

CorTechs Labs Presents Findings Regarding Alzheimer’s Disease at the Radiological Society of North America’s (RSNA) 2019 Annual Meeting

Retrieved on: 
Monday, December 2, 2019
Biotechnology, Practice Management, Technology, Other Health, Health, General Health, Radiology, Mental health, Other Technology, Medical devices, Software, Branches of biology, Medicine, Biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, RTT, Alzheimer's disease, Mild cognitive impairment, Biomarker, Aging brain, Alzheimer's Disease Neuroimaging Initiative

CorTechs Labs Inc. , the leading quantitative neuroimaging software company, announced today they will be exhibiting at RSNA 2019 , which is taking place from December 1-6, 2019.

Key Points: 
  • CorTechs Labs Inc. , the leading quantitative neuroimaging software company, announced today they will be exhibiting at RSNA 2019 , which is taking place from December 1-6, 2019.
  • CorTechs Labs recently developed a machine learning based age-prediction model for metabolic and volumetric changes of normal brain structures and evaluated this model on imaging data from patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), as well as control subjects.
  • The company will be presenting its findings at the conference around the understanding that determining brain aging may be critical to identify potential biomarkers in neurodegenerative diseases, such as Alzheimers disease.
  • Our goal is to supply innovative technology that enables physicians to provide excellent care with a very high degree of accuracy, said Chris Airriess, chief executive officer of CorTechs Labs.

Groundbreaking Memory Research Shows Amazonian Plant Extract PTI-00703 Cat's Claw as Potent Inhibitor and Reducer of Both Brain Plaques and Tangles

Retrieved on: 
Tuesday, March 5, 2019
Senescence, Aphasias, Neuroscience, Branches of biology, Cognitive science, RTT, Cognitive disorders, Psychiatric diagnosis, Aging brain, Memory and aging, Memory, Alzheimer's disease

EDMONDS, Washington, March 5, 2019 /PRNewswire/ --Scientific Reportsrecently published a landmark research paper which has immediate favorable implications for brain health and memory loss in the aging brain.

Key Points: 
  • EDMONDS, Washington, March 5, 2019 /PRNewswire/ --Scientific Reportsrecently published a landmark research paper which has immediate favorable implications for brain health and memory loss in the aging brain.
  • The research paper, which can be accessed at https://www.nature.com/articles/s41598-019-38645-0 was authored by world renowned brain-aging and Alzheimer's disease researcher Dr. Alan Snow.
  • Snow continued, "This is a huge step forward in the fields of brain health, brain aging and the study of age-related memory loss.
  • Snow has been studying brain aging, memory loss, and brain plaques and tangles for over 30 years and presently serves as founder and CEO of Edmonds, Washington-based Cognitive Clarity Inc.

New Generation of Therapeutics Based on Understanding of Aging Biology Show Promise for Alzheimer's Disease

Retrieved on: 
Friday, December 7, 2018
Neuroscience, Biology, Medicine, Senescence, Aphasias, Cognitive disorders, Psychiatric diagnosis, RTT, Alzheimer's disease, Aging brain, Gladstone Institutes, Alzheimer's disease research

"Decades of research have revealed common processes that are relevant to understanding why the aging brain is vulnerable to Alzheimer's disease.

Key Points: 
  • "Decades of research have revealed common processes that are relevant to understanding why the aging brain is vulnerable to Alzheimer's disease.
  • New therapeutics for Alzheimer's disease will come from this understanding of the effects of aging on the brain."
  • The only approved medications for Alzheimer's disease relieve some symptoms but do not halt disease progression.
  • And, aging biology provides numerous novel targets for new drug development for Alzheimer's disease, notes Dr. Fillit.